Current knowledge on diagnosis and staging of neuroendocrine tumors

被引:0
作者
Kjell Öberg
Daniel Castellano
机构
[1] Uppsala University Hospital,Department of Endocrine Oncology
[2] University Hospital 12 de Octubre,Medical Oncology Department
来源
Cancer and Metastasis Reviews | 2011年 / 30卷
关键词
Neuroendocrine tumor; GEP-NETs; WHO classification; TNM staging; Molecular imaging; Biomarkers;
D O I
暂无
中图分类号
学科分类号
摘要
Neuroendocrine tumors (NETs) consist of a heterogeneous group of malignancies with various clinical presentations and growth rates. The incidence has been estimated to 2.5–5 per 100,000 people per year and prevalence of 35 per 100,000. The largest group is the gastroenteropancreatic NETs. Small intestinal NETs are the most common followed by pancreatic NETs in the gastrointestinal tract. A classification system (World Health Organization) was established in year 2000 and recently updated in 2010, taking into consideration the histopathology and tumor biology of the tumors. To further refine the classification a “tumor node metastasis” staging has been suggested by the European Neuroendocrine Tumor Society. The same organization has also proposed a grading system (G1, G2, and G3). The diagnosis of a NET is based on histopathology on tumor specimens, circulating biomarkers as well as imaging. Traditional radiology, such as computerized tomography and magnetic resonance imaging, is still the basis but is complemented with somatostatin receptor scintigraphy and positron emission tomography with specific isotopes such 68Ga-DOTA-octreotate, F18-dopamine, or C11-5 hydroxytryptamine. Molecular imaging will increase in importance in the near future. There is still an unmet need for more sensitive biomarkers for diagnosis and follow-up.
引用
收藏
页码:3 / 7
页数:4
相关论文
共 81 条
[1]  
Lubarsch O(1867)Ueber den primaren Krebs des Ileum, nebst Bemerkungen über das gleichzeitige Vorkommen von Krebs und Tuberkuolose Virchow Archiv Pathol Anatom Physiol Klin Med 111 280-317
[2]  
Modlin IM(2008)Gastroenteropancreatic neuroendocrine tumours The Lancet Oncology 9 61-72
[3]  
Oberg K(2003)A 5-decade analysis of 13,715 carcinoid tumors Cancer 97 934-59
[4]  
Chung DC(2005)Current status of gastrointestinal carcinoids Gastroenterology 128 1717-51
[5]  
Modlin IM(2005)Somatostatin-receptor mediated diagnosis and treatment in gastrointestinal neuroendocrine tumours (GEP-NET’s) Roczniki Akademii Medycznej w Bialymstoku 50 62-8
[6]  
Lye KD(2003)Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for European Journal of Nuclear Medicine and Molecular Imaging 30 781-93
[7]  
Kidd M(2005) multireceptor tumour targeting The Journal of Endocrinology 184 11-28
[8]  
Modlin IM(2010)Hypothalamic hormones a.k.a. hypothalamic releasing factors Gastroenterology 139 742-53
[9]  
Kidd M(2004)Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy European Journal of Endocrinology 151 107-12
[10]  
Latich I(2002)High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours Journal of Nuclear Medicine 43 610-6